drugset / Trial / NCT00214461

Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers

NCT00214461 ↗

Phase 1 Completed 48 enrolled Sanofi
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine the safety and tolerability of a modified C. difficile vaccine at 3 dose levels compared with a placebo control administered via intramuscular injection in healthy elderly subjects aged \> or = 65 years. This is the companion study to H-030-008, in which healthy younger adults have already been dosed.

Timeline

Start
2005-11
Primary completion
2006-02
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject C. difficile Toxoid Vaccine Vaccine 2 ug Intramuscular
Subject C. difficile Toxoid Vaccine Vaccine 10 ug Intramuscular
Subject C. difficile Toxoid Vaccine Vaccine 50 ug Intramuscular